tiprankstipranks
Advertisement
Advertisement
Plus announces presentation of health economics study on CNSide CSF assay
PremiumThe FlyPlus announces presentation of health economics study on CNSide CSF assay
2M ago
Plus Therapeutics enters pact with Ephemeral for AI execution platform
Premium
The Fly
Plus Therapeutics enters pact with Ephemeral for AI execution platform
2M ago
Plus Therapeutics Stockholders Back Directors and Incentive Plan
Premium
Company Announcements
Plus Therapeutics Stockholders Back Directors and Incentive Plan
2M ago
Plus Therapeutics Appoints New Chief Development Officer
PremiumCompany AnnouncementsPlus Therapeutics Appoints New Chief Development Officer
3M ago
Plus Therapeutics appoints Eric Daniels as chief development officer
Premium
The Fly
Plus Therapeutics appoints Eric Daniels as chief development officer
3M ago
Plus Therapeutics Gains FDA Orphan Status for REYOBIQ
Premium
Company Announcements
Plus Therapeutics Gains FDA Orphan Status for REYOBIQ
4M ago
Plus Therapeutics Enacts Reverse Stock Split to Maintain Listing
PremiumCompany AnnouncementsPlus Therapeutics Enacts Reverse Stock Split to Maintain Listing
4M ago
Plus Therapeutics Inc (USA) trading halted, news pending
Premium
The Fly
Plus Therapeutics Inc (USA) trading halted, news pending
4M ago
Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital
Premium
The Fly
Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100